Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Diagnostics for applications in oncology—particularly immuno-oncology—continued to be the most common focus of dealmaking in the past 12 months, while deals related to Alzheimer’s disease and infectious disease threats such as Zika virus infection were also prominent.
Although the volume and value of merger and acquisition (M&A) deals in the medtech industry both increased in 2016 compared with 2015, M&A activity declined during the year, reflecting the challenges that the industry faces.
Despite the volatility of biotech stocks in the public markets, the VC-backed private biotech ecosystem has been in remarkable equilibrium for much of the last decade.
Exploration by biopharma companies of new biological pathways underlying skin disorders is leading to the entry of potential blockbusters into the dermatology market, and fueling high-value deals.
Partnering activity in the microbiome space exploded in 2016, and with the first inroads into clinical development well under way, 2017 is shaping up as a pivotal year for the microbiome’s therapeutic and market potential to blossom.
Universities have long been viewed as important to the economic and social well-being of their communities, but in recent years expectations have changed.
The number of mergers and acquisitions in the pharmaceutical industry has continued to rise, with oncology being a particularly active area and assets increasingly being acquired at earlier stages of their development.
The potential of nucleic-acid-based drugs to halt the production of disease-associated proteins or to promote the production of therapeutic proteins has spurred a string of recent deals.
After safety issues dashed hopes several years ago, calcitonin-gene related peptide has re-emerged as a prominent target, catalyzing deals and potentially reinvigorating the generic-dominated migraine market.
Progress in tackling technical challenges in the development of bispecific antibodies and emerging opportunities in the red-hot immuno-oncology space have catalyzed a flurry of dealmaking activity for bispecific platform companies.
The clinical impact of checkpoint inhibitors and their anticipated position as linchpins of future cancer immunotherapy regimens has driven a wave of dealmaking. In this feature, we chart the development progress and major deals for the leading checkpoint inhibitors.
A trend toward outsourcing early-stage R&D and thriving capital markets over the past few years have helped platform biotechs remain independent and able to ink creative deals with pharma companies.
Academic partnering is undergoing a period of great diversification and growth, with new forms of collaboration between academia and industry, such as the open innovation model, setting the stage for a fertile crop of partnerships.
The pharmaceutical and biotechnology industries see over 3,000 deals signed every year, many of which involve the complex and often unfamiliar process of valuing potential products that are not yet on the market. In this feature, valuation specialists Venture Valuation explain how the value of a product is calculated and how this relates to the overall deal value.
Recently announced inflammation deals selected by BioPharma Dealmakers highlight the approaches companies are taking to target disorders in this area, specifically those affecting the gastrointestinal system.
After a slow arrival, digital advances in health care are now progressing rapidly. Boosted by a $4.5 billion investment in 2015, the digital health market is now seeing the development of a wave of wearable and mobile technologies to monitor, control and collect data on many of today’s diseases.
